2. 您的位置
3. 首页
4. 会议论文
5. ELOQUENT-2: A phase Ⅲ, randomized, open-label study of lenalidomide (Len)/dexamethasone (dex) with/w

ELOQUENT-2: A phase Ⅲ, randomized, open-label study of lenalidomide (Len)/dexamethasone (dex) with/w

来源 :2015年临床肿瘤学新进展学术研讨会 | 被引量 : 0次 | 上传用户：gaolei19890917

【作 者】

：

Sagar Lonial Meletios A. Dimopoulos Antonio Palumbo Darrell White Sebastian Grosicki Ivan Spicka Adam Walter-Croneck Philippe Moreau María-Victoria Mateos Hila Magen-Nativ Andrew Belch Donna Ellen Ree 

【机 构】

：

Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA

【出 处】

：

2015年临床肿瘤学新进展学术研讨会

【发表日期】

：

2015年3期

下载到本地 , 更方便阅读

下载此文 赞助VIP

声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架

论文部分内容阅读

其他文献

Chemotherapy-related cognitive impairment (CRCI), and neurotransmitter signaling, longevity, and inf

会议

CALGB 70604 (Alliance): A randomized phase Ⅲ study of standard dosing vs. longer interval dosing of

会议

Successful implementation of a novel trial model: The Signature program.

会议

A pharmacokinetically (PK) and pharmacodynamically (PD) driven phase I trial of the pan-AKT inhibito

会议

A phase I study of PF-05082566 (anti-4-1BB) + rituximab in patients with CD20+ NHL

会议

Phase Ⅱ multicenter proof of concept study of AZD4547 in FGFR amplified tumours

会议

Safety and efficacy of MEDI4736, an anti-PD-L1 antibody, in patients from a squamous cell carcinoma

会议

Efficacy based on tumor PD-L1 expression in KEYNOTE-002, a randomized comparison of pembrolizumab (p

会议

GADOLIN: Primary results from a phase Ⅲ study of obinutuzumab plus bendamustine compared with bendam

会议

Phase Ⅱ study of daratumumab (DARA) monotherapy in patients with ≥ 3 lines of prior therapy or doubl

会议